ATAGI advice on RSV vaccine
06 Aug 2025
An update on the administration of respiratory syncytial virus (RSV) immunisation products by healthcare providers has been issued, following recent reports of incorrect use of some products.
The Australian Technical Advisory Group on Immunisation (ATAGI) has issued a statement to emphasise the importance of correct administration of RSV immunisation products, following reports made to the Therapeutic Goods Administration, and state and territory authorities.
In Australia, the Arexvy RSV vaccine is now approved, as well as Abrysvo, which is on the National Immunisation Program for pregnant women at 28–36 weeks gestation.
The new ATAGI statement includes:
- a table of RSV immunisation product indications and recommendations
- a guide on steps to take in the event of incorrect administration, including following existing clinical guidance on errors, and reporting the event
- a guide on practical measures GPs can take to minimise the chance of errors, such as storage advice and procedural checklists.
ATAGI advises use of the update in conjunction with the RSV chapter of the Australian Immunisation Handbook and emphasises the comprehensive screening of people before administering immunisation products, ensuring they are familiar with all guidance, especially on newer products.
So far this year, more than 120,000 cases of RSV infection have been reported nationally.